Viking Therapeutics, Inc. — Operating Income by Fiscal Year
12 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/f7afcd5f-b56a-425d-aa1f-04c4d1875c2b/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-393.3M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-046876 |
| FY 2024 | $-150.9M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-027824 |
| FY 2023 | $-100.8M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-012322 |
| FY 2022 | $-70.4M | 2022-01-01 – 2022-12-31 | evidence 0001564590-23-001685 |
| FY 2021 | $-55.7M | 2021-01-01 – 2021-12-31 | evidence 0001564590-22-004429 |
| FY 2020 | $-42.7M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-006406 |
| FY 2019 | $-32.7M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-006766 |
| FY 2018 | $-26.2M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-007584 |
| FY 2017 | $-19.1M | 2017-01-01 – 2017-12-31 | evidence 0001564590-19-007584 |
| FY 2016 | $-13.8M | 2016-01-01 – 2016-12-31 | evidence 0001564590-17-004911 |
| FY 2015 | $-12.0M | 2015-01-01 – 2015-12-31 | evidence 0001564590-16-014212 |
| FY 2014 | $-23.5M | 2014-01-01 – 2014-12-31 | evidence 0001564590-16-014212 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Viking Therapeutics, Inc. — all facts · Revenue · Net Income